Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects (Q74596886)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604899%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

review article

1 reference

title

Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604899%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

J Davignon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604899%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

language of work or name

English

0 references

publication date

1 April 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604899%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Cardiology

11 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604899%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604899%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

8A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604899%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

17F-24F

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604899%20AND%20SRC:MED&resulttype=core&format=json

Emerging strategies for the treatment of atherosclerosis as seen from the patent literature

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Probucol reduces plasma lipid peroxides in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Probucol inhibits oxidative modification of low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Probucol protects lipoprotein (a) against oxidative modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atheroscleros

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Prevention of atherosclerotic progression in Watanabe rabbits by probucol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Probucol and other antioxidants prevent the inhibition of endothelium-dependent relaxation by low density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Ultraviolet-treated lipoproteins as a model system for the study of the biological effects of lipid peroxides on cultured cells. III. The protective effect of antioxidants (probucol, catechin, vitamin E) against the cytotoxicity of oxidized LDL occu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Oxidized low-density lipoprotein is cytotoxic to human monocyte-macrophages: protection with lipophilic antioxidants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Protective effects of probucol against glutamate-induced cytotoxicity in neuronal cell line PC12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Inhibition of IL-1 beta expression in THP-1 cells by probucol and tocopherol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Inhibitory effect of a single local probucol administration on neointimal formation in balloon-injured rat carotid artery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Copper-induced tissue factor expression in human monocytic THP-1 cells and its inhibition by antioxidants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Protective effect of probucol on alloxan diabetes in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

MDL 29311. Antioxidant with marked lipid- and glucose-lowering activity in diabetic rats and mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Clinical trials of antioxidants in atherosclerosis: are we doing the right thing?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Effect of fibric acid derivatives on blood lipid and lipoprotein levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Pharmacokinetics of clofibrate in familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Inhibition of the production of infectious herpes simplex virus by clofibrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Protection against acetaminophen hepatotoxicity by a single dose of clofibrate: effects on selective protein arylation and glutathione depletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Reduction of Lp(a) plasma levels by bezafibrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Comparison of lovastatin and bezafibrate on lipoprotein(a) plasma levels in cardiac transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Safety and efficacy of lifibrol upon four-week administration to patients with primary hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Altering Triglyceride Concentrations Changes Insulin-Glucose Relationships in Hypertriglyceridemic Patients: Double-Blind Study With Gemfibrozil With Implications for Atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Long-term effects of simvastatin in familial dysbetalipoproteinaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Pravastatin, lipids, and major coronary events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Effects of simvastatin and pravastatin on endothelium-dependent relaxation in hypercholesterolemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Effect of pravastatin on outcomes after cardiac transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Simvastatin-sodium delays cell death of anoxic cardiomyocytes by inhibition of the Na+/Ca2+ exchanger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Comment: lovastatin-induced rhabdomyolysis in the absence of concomitant drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Lovastatin decreases coenzyme Q levels in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

Ex vivo lipopolysaccharide-induced interleukin-1 secretion from murine peritoneal macrophages inhibited by probucol, a hypocholesterolemic agent with antioxidant properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900253-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(98)00253-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604899%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference